MREO · Mereo BioPharma Group plc
AI read · Bad for MREO
The AI's read
Mereo filed an 8-K flagging a notice of delisting for failing to meet continued listing standards. Delisting threatens liquidity, listing status and could shave market cap quickly. The market is already down about 3.9% on the news and RSI sits at 26.93, so shares look oversold but under fresh stress. Volume is modest, which magnifies downside when sellers press. Because the catalyst is new and severe, we lean bearish on near-term price action with 84% conviction. The main playbook risk is a trading suspension or transfer to an OTC venue that cripples liquidity.